Please login to the form below

Not currently logged in

Shire enters research partnership for rare eye disease

Will work with Foundation Fighting Blindness on treatment for adRP

Shire BasingstokeShire and the Foundation Fighting Blindness have entered a research agreement to find novel treatments for aurosomal dominant retinitis pigmentosa (adRP).

The rare genetic disease usually first occurs in late childhood or adolescence and is typically followed by the progressive loss of peripheral vision.

As part of the agreement, the Foundation and its research partners will provide Shire with knowledge and scientific background regarding adRP in addition to clinical information that could progress findings.

Albert Seymour, senior VP of global research and non-clinical development at Shire, commented: “This agreement is an example of the creative approaches in early-stage rare disease research and development that we are taking at Shire.

“Both organisations have a strong, shared commitment to unearthing and developing innovative treatments in areas of significant, unmet medical need.”

The Foundation will also provide counsel where necessary concerning pre clinical and clinical development of Shire compounds in the development process.

Shire will in turn compensate the Foundation and makes its own expertise and experience in investigational new drug applications available when needed.

Patricia Zilliox, chief drug development officer at the Foundation Fighting Blindness Clinical Research Institute, added: “Through our agreement with Shire, we are excited to drive research and development and extend our expertise to dedicated partners working to accelerate treatments for those living with retinal diseases.”

Article by
Kirstie Pickering

6th May 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...